INCY
Incyte
$103.66
▲ 5.5%Updated Today 6:01 PM ET
▲ Up 43.9% over the last 12 months
Market Cap
$19.62B
P/E
13.73x
Forward P/E (est.)
9.81x
ROE
29.2%
Revenue Growth
21.5%
EPS Growth
2455.3%
Profit Margin
26.7%
FCF Yield
2.2%
Debt / Equity
0.01x
ROIC
5.0%
Interest Coverage
593.83x
Current Ratio
3.68x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
86/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what INCY's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. INCY trades near $103.66, above its 50-day average ($98.12) and 200-day average ($96.74). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 52 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. INCY's is $4.45 (~4.3% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month INCY found buyers near $92.18 (support) and sellers near $110.34 (resistance); its 52-week range is $66.74–$112.29. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.9× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Incyte (INCY) is a large-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500, with a market value around $19.62B.
In its latest reported year it generated about $5.14B in revenue and $1.29B in net profit.
Our model rates INCY Strong (86/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
14.5%
Revenue moved from $2.99B in 2021 to $5.14B in 2025, a 14.5% compound annual growth rate. The most recent year grew a strong 21.5% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
93.0%
Operating Margin
29.5%
Net Margin
25.0%
ROE
29.2%
Incyte keeps about 26.7% of each sales dollar as net profit, with a 93.0% gross margin and 29.5% operating margin. Return on equity is 29.2% and return on invested capital about 5.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$19.09B
Net Debt
$15.63B
Net Debt / EBITDA
10.32x
Debt / Equity
0.01x
Leverage: debt-to-equity is 0.0x, and operating profit covers interest about 593.8x, with a current ratio of 3.7x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $19.09B of total debt against $3.46B of cash.
Operating CF
$1.41B
Free Cash Flow
$1.41B
FCF Margin
27.5%
In the latest year Incyte produced about $1.41B of operating cash flow and $1.41B of free cash flow after capital spending. That is a free-cash-flow yield of about 2.2% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
13.73x
P/S
3.88x
P/B
3.69x
EV / EBITDA
22.11x
INCY trades at 13.7x trailing earnings (about 9.8x on estimated forward earnings), 3.9x sales, and 3.7x book value. That is an undemanding multiple — potentially cheap if the business is stable.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How INCY stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), INCY ranks #1 of 59 by our overall rating. It trades at a discount versus the sector on earnings (13.7x P/E vs. 25.4x median) with a higher return on equity (29.2% vs. 14.9%) and faster revenue growth (21.5% vs. 7.9%).
P/E vs sector
13.7x
median 25.4x
ROE vs sector
29.2%
median 14.9%
Growth vs sector
21.5%
median 7.9%
Sector rank
#1
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$133.50 – $233.62
vs. $103.66 today · expected CAGR 5% – 18%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $6.22B | $7.53B | $9.11B | $11.02B | $13.34B |
| Net income | $1.56B | $1.88B | $2.28B | $2.76B | $3.33B |
| EPS | $7.78 | $9.42 | $11.40 | $13.79 | $16.69 |
| Share price (low) | $62.28 | $75.36 | $91.18 | $110.33 | $133.50 |
| Share price (high) | $108.98 | $131.87 | $159.56 | $193.07 | $233.62 |
| CAGR (low–high) | -40% / 5% | -15% / 13% | -4% / 15% | 2% / 17% | 5% / 18% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for INCY:
- Revenue is growing 21.5% a year, a sign of real demand.
- High net margins (26.7%) point to pricing power or efficiency.
- Strong return on equity (29.2%) shows capital is put to work well.
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
- Our model's overall read is Strong (86/100).
The case against INCY:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Incyte is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 13.7x earnings, which our model scores Strong (86/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.